Abstract
The Supreme Court recently ruled on the scope of the patent infringement 'safe harbour' of 35 U.S.C. §271(e)(1), which was passed by Congress in 1984 to allow generic drug manufacturers to test their drugs before the expiration of the patents that covered the drugs. The scope of the safe harbour has been interpreted by the courts to be much broader than that, and the Supreme Court confirmed the breadth of the exemption. The Supreme Court did not, however, address the application of the safe harbour to research tools, an issue of vast commercial importance. This paper traces the history of the safe harbour and the Merck v Integra decision, and explains the current state of the law and where the law may be going.
Subject
Management of Technology and Innovation,Economics and Econometrics,Biotechnology
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献